Table I.

Characteristics of the 69 patients grouped by the G/T ratio of tumor-infiltrating lymphoid cells

VariableG/T ≤ 5.2 (n = 35)G/T > 5.2 (n = 34)
Gender: female18 (51%)15 (44%)
Median age6457.5
Tumor site: head31 (89%)30 (88%)
Tumor size > 3 cm9 (25%)15 (44%)
Stage IIB/III26 (74%)31 (91%)
Grade 311 (31%)12 (35%)
Karnofsky >8024 (69%)21 (62%)
Surgical margin R112 (34%)15 (44%)
Median preoperative CA19.9217 ± 3453.8 range (1–18,470)94 ± 1342.6 range (1–6,832)
Median postoperative CA19.916 ± 88.8 range (1–416)23 ± 678.6 range (0.1–3,745)
aTreatment: PEFG18 (51%)20 (59%)
  • a Patients who had R0 or R1 resection of a stage IB-III pancreatic cancer, aged 18–75 yr and Karnofsky Performance Status (KPS) > 60, were eligible for adjuvant therapy. The patients were required to have postoperative treatment initiation within 2 mo from surgery, no previous chemotherapy or radiotherapy for pancreatic cancer, and adequate bone marrow, liver, and kidney. After tumor resection, 31 patients were treated with gemcitabine (Burris et al., 1997) and 38 patients received the PEFG regimen consisting of cisplatin, epirubicin, gemcitabine, and 5-fluorouracil (Reni et al., 2005). In both cases, chemotherapy was administered for 3 mo followed by chemoradiation (Reni et al., 2005).